Corvus Pharmaceuticals (CRVS) Treasury Shares (2015)
Corvus Pharmaceuticals (CRVS) posted quarterly Treasury Shares of $400000.0 for Q3 2024, little changed quarter-over-quarter from $400000.0 in Q2 2024.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Treasury Shares (2015) Analysis & Trends
Corvus Pharmaceuticals' Treasury Shares history runs 7 years deep, the most recent figure standing at $400000.0 for Q3 2024.
- In Q3 2024, Treasury Shares changed N/A year-over-year to $400000.0; the TTM figure through Sep 2024 stood at $400000.0 (changed N/A YoY), while the FY2023 annual figure was $400000.0, changed N/A from the prior year.
- Treasury Shares for Q3 2024 stood at $400000.0, roughly flat from $400000.0 in the prior quarter.
- The five-year high for Treasury Shares was $400000.0 in Q4 2023, with the low at $400000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 2.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | - |